Research and Markets: Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rm43t6/adrenoleukodystrop) has announced the addition of Global Markets Direct's new report "Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2012" to their offering.

“Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2012”

Global Markets Direct's, 'Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline.

This report provides information on the therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex).

Scope

- A snapshot of the global therapeutic scenario for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex).

- A review of the Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/rm43t6/adrenoleukodystrop

Source: Global Markets Direct